Hematology Today—May 25, 2026

LucidQuest

4 hours ago

This week’s Hematology update highlights regulatory approvals, reimbursement activity, gene therapy expansion, clinical data releases, and advancing cell and AI-enabled therapeutic strategies.

In Today’s Newsletter

Dive deeper

💊 PYRUKYND EU thalassaemia approval [1] [EU • 22 May 2026]

https://www.avanzanite.com/news/pyrukynd-eu-approval-thalassaemia
Context: PYRUKYND (mitapivat, Agios; commercialized in Europe by Avanzanite) is an oral pyruvate kinase activator.
Key point: European Commission approved PYRUKYND for adults with anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia.
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 First Canadian HEMGENIX treatment outside trial [2] [Canada • 20 May 2026]

https://www.newswire.ca/news-releases/csl-canada-announces-first-canadian-patient-receives-hemgenix-r-etranacogene-dezaparvovec-hemophilia-b-gene-therapy-in-ontario-canada-882116953.html
Context: HEMGENIX (etranacogene dezaparvovec, CSL) is a one-time gene therapy for eligible adults with hemophilia B.
Key point: CSL Canada said the first Canadian patient received HEMGENIX outside a clinical trial at London Health Sciences Centre.
Implication: May expand screening, initiation, and follow-up at scale.

🩸 CLN-049 FDA Orphan Drug Designation in AML [3] [US • 19 May 2026]

https://investors.cullinantherapeutics.com/news-releases/news-release-details/cullinan-therapeutics-receives-fda-orphan-drug-designation-cln
Context: CLN-049 (Cullinan Therapeutics) is an investigational FLT3xCD3 T cell engager in Phase 1 studies.
Key point: FDA granted Orphan Drug Designation to CLN-049 for relapsed/refractory acute myeloid leukemia.
Implication: Signals pipeline investment and modality expansion.

🎯 Blenrep pCPA negotiations in Canada [4] [Canada • 20 May 2026]

https://ca.gsk.com/en-ca/media/press-releases/gsk-and-the-pan-canadian-pharmaceutical-alliance-pcpa-initiate-negotiations-for-blenrep-for-the-treatment-of-relapsed-or-refractory-multiple-myeloma/
Context: Blenrep (belantamab mafodotin, GSK) is an anti-BCMA antibody-drug conjugate.
Key point: GSK and pCPA initiated negotiations for Blenrep combinations in adults with relapsed or refractory multiple myeloma.
Implication: May influence prescriber choice and payer reviews pending full data.

🤖 GC Biopharma AI tool for hemophilia joint risk [5] [Korea • 22 May 2026]

https://www.mk.co.kr/en/it/12055552
Context: GC Biopharma is developing an AI-based clinical decision-support system with the Korea Hemophilia Foundation, Seoul National University College of Pharmacy, and Samsung Medical Center.
Key point: The project will use long-term Korean clinical data and X-ray images to predict future hemophilia joint damage risk.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

📊 Ropeginterferon alfa-2b ASCO/EHA data [6] [US • 22 May 2026]

https://www.businesswire.com/news/home/20260522629650/en/PharmaEssentia-to-Present-New-Clinical-Data-Supporting-the-Use-of-Ropeginterferon-Alfa-2b-in-Essential-Thrombocythemia-at-ASCO-and-EHA-2026
Context: PharmaEssentia will present SURPASS-ET and EXCEED-ET analyses in essential thrombocythemia at ASCO and EHA 2026.
Key point: Source reports durable hematologic and molecular responses, with earlier ropeginterferon alfa-2b use supporting disease-control analyses.
Implication: May influence prescriber choice and payer reviews pending full data.

🧫 KLN-1010 Fast Track and ASCO/EHA updates [7] [US • 21 May 2026]

https://keloniatx.com/kelonia-therapeutics-to-present-updated-clinical-data-at-2026-american-society-of-clinical-oncology-asco-annual-meeting-and-european-hematology-association-eha-2026-congress/
Context: KLN-1010 (Kelonia Therapeutics) is an investigational in vivo anti-BCMA CAR-T gene therapy for relapsed/refractory multiple myeloma.
Key point: FDA granted Fast Track designation, and updated Phase 1 inMMyCAR data will be presented at ASCO and EHA 2026.
Implication: Signals pipeline investment and modality expansion.

Why it matters

Rare hematology therapies are moving from regulatory milestones into real-world implementation, with PYRUKYND gaining EU approval and HEMGENIX reaching first post-trial use in Canada.
Multiple myeloma remains a major commercial and clinical focus, with both reimbursement activity for Blenrep and continued investment in next-generation BCMA-directed approaches such as KLN-1010.
Regulatory designations continue to support development momentum in high-need blood cancers, including FDA Orphan Drug Designation for CLN-049 in relapsed/refractory AML and Fast Track status for KLN-1010.
ASCO and EHA 2026 are emerging as important catalysts for hematology pipeline visibility, particularly in essential thrombocythemia and relapsed/refractory multiple myeloma.
AI-enabled monitoring and prediction tools are entering hematology care pathways, highlighted by GC Biopharma’s effort to predict hemophilia joint disease progression using longitudinal clinical and imaging data.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Hematology archive on our research hub page.

FAQ

What did the European Commission approve for PYRUKYND?

PYRUKYND (mitapivat) was approved for adults with anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia. [1]

What is notable about HEMGENIX in Canada?

CSL Canada said the first Canadian patient received HEMGENIX outside a clinical trial at London Health Sciences Centre, following public reimbursement in Ontario and British Columbia. [2]

What is CLN-049 and what did FDA grant?

CLN-049 is Cullinan Therapeutics’ investigational FLT3xCD3 T cell engager. FDA granted Orphan Drug Designation for relapsed/refractory AML. [3]

Which Blenrep regimens are in pCPA negotiations?

GSK cited Blenrep with bortezomib and dexamethasone, and Blenrep with pomalidomide and dexamethasone, for eligible adults with relapsed or refractory multiple myeloma. [4]

What is GC Biopharma building for hemophilia care?

GC Biopharma is developing an AI-based clinical decision-support system to predict hemophilia joint disease using clinical data and X-ray images. [5]

What is KLN-1010 designed to do?

KLN-1010 is designed to generate anti-BCMA CAR T-cells in vivo after a single infusion, without bespoke CAR-T manufacturing or preparative chemotherapy. [7]

Entities / Keywords

PYRUKYND, mitapivat, Agios Pharmaceuticals, Avanzanite Bioscience, thalassaemia, alpha-thalassaemia, beta-thalassaemia, ENERGIZE, ENERGIZE-T
HEMGENIX, etranacogene dezaparvovec, CSL Canada, hemophilia B, Factor IX, HOPE-B
CLN-049, Cullinan Therapeutics, FLT3xCD3, T cell engager, relapsed/refractory AML, acute myeloid leukemia
Blenrep, belantamab mafodotin, GSK Canada, pCPA, BCMA, relapsed/refractory multiple myeloma
GC Biopharma, hemophilia arthropathy, AI, clinical decision-support system, CDSS, X-ray analysis
Ropeginterferon alfa-2b, BESREMi, PharmaEssentia, essential thrombocythemia, polycythemia vera, SURPASS-ET, EXCEED-ET
KLN-1010, Kelonia Therapeutics, inMMyCAR, in vivo CAR-T, BCMA, iGPS, Fast Track